Objective: Triple-negative breast cancer (TNBC) is highly invasive and metastatic, which is in urgent need of transformative therapeutics. Tubeimu (TBM), the rhizome of Bolbostemma paniculatum (Maxim.) Franquet, is one of the Chinese medicinal herbs used for breast diseases since the ancient times. The present study evaluated the efficacy, especially the anti-metastatic effects of the dichloromethane extract of Tubeimu (ETBM) on TNBC orthotopic mouse models and cell lines.
Introduction
Breast cancer accounts for nearly one fourth of cancer cases worldwide and is the dominant cause of cancer death in breast cancer cases (1, 3, 4) . The treatment for TNBC patient is very limited since it's a metastatic recalcitrant cancer (5-7) with very poor prognosis (8) (9) (10) (11) (12) . Therefore, transformative therapeutics are needed for TNBC.
Tubeimu (TBM), the rhizome of Bolbostemma paniculatum (Maxim.) Franquet, is a Traditional Chinese Medicinal (TCM) herb that has been used for the treatment of breast diseases, including breast cancer, for over 270 years (13) . TBM has many pharmacological activities, including antitumor and anti-inflammatory efficacy (14, 15) , and has shown suppressive activity against several cancer cell lines, including nasopharyngeal (16) and liver (17, 18) cancer cells.
The human breast cancer cell line MDA-MB-231 is derived from TNBC pleural effusion (19, 20) and is invasive (21, 22) . In a previous study, we has demonstrated that the dichloromethane extract of TBM (ETBM) induced apoptosis of MDA-MB-231 TNBC cells in both twodimensional and three-dimensional culture (23) , but further studies are to be conducted to investigate the efficacy of ETBM on in vivo tumor formation and cell functions.
Therefore, we designed the present study to evaluate the efficacy of ETBM on different TNBC cell lines and MDA-MB-231 mice model. An orthotopic animal model of MDA-MB-231 was generated as it would enable a more clinical-like pattern of metastasis (24, 25) , while cancer cells expressing green fluorescent protein (GFP) enable realtime visualization and easier quantification of tumor growth (26) . We also performed mRNA sequencing to have a more comprehensive understanding of which biological pathways ETBM might have influenced. Finally, quantitative real-time polymerase chain reactions (qRT-PCR), Western blotting and immunohistochemical (IHC) staining were used to confirm the change of expression on Rho GTPase activating protein 5 (ARHGAP5), integrin β1 (ITGβ1), and integrin β8 (ITGβ8) in focal adhesion pathways.
Materials and methods

Cell lines
MDA-MB-231-GFP human TNBC cells were obtained from AntiCancer, Inc. (San Diego, CA, USA) and cultured in RPMI-1640 (Gibco-BRL, Life Technologies, Inc., Carlsbad, CA, USA). MDA-MB-468 and SUM-149 were originally obtained from American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in Dulbecco's modified eagle medium (DMEM)-high glucose (Gibco, Thermo Fisher Scientific, MA, USA). The 10% fetal bovine serum (FBS; Gibco) and penicillinstreptomycin antibiotic mixture (10 ml/L; Gibco) were added to the medium and cells were incubated in a 5% CO 2 atmosphere at 37 °C.
ETBM agent
Fresh rhizomes of Bolbostemma paniculatum were collected in the Anguo City of Hebei Province in China (38.398 56°N; 115.348 43°E; altitude 28 m). The plant was identified and extracted with dichloromethane by the Pharmacy School of Beijing University of Chinese Medicine. Then it was dissolved in phosphate-buffered saline (PBS) with 10% of dimethyl sulfoxide (DMSO) for making a 1,000× ETBM solution. It was sterilized through a syringe with a 0.22 μm filter. ETBM was stored at -20 °C in eppendorf tubes and mixed with the medium for working concentrations. The 0.1% DMSO was used as control in in vitro studies.
Cell proliferation assay
In order to better visualize and quantitate ETBM activity on MDA-MB-231-GFP cells in vitro, we used the IncuCyte ® ZOOM live-cell assay, which photographed each well on an hourly basis. Cells were plated into 96-well plates at 15,000 cells/well. Phase contrast and green fluorescence of the wells was monitored for a 24- 
Invasion/migration assay
Transwell inserts (Corning Inc., NY, USA) with 8 μm pore size with and without Matrigel (Collaborative Research Products, Bedford, MA, USA) were used. Cells were pretreated with 1% serum with no TBM, 30 μg/mL or 60 μg/mL TBM for 24 h and then mitomycin for 2 h. Following Matrigel rehydration with serum-free media, cells were seeded at a density of 10 4 per insert. The lower chamber was loaded with 450 μL RPMI-1640 containing 10% FBS. After 24 h incubation, cells that migrated through to the other side of the insert were fixed in 4% formalin, stained with 0.5% (weight/volume) crystal violet, and counted under a microscope.
Establishment of orthotopic breast cancer model
Animal experimental protocols were approved by the Animal Care and Protection Committee of Dongfang Hospital, Beijing University of Chinese Medicine (Approval No. 201540). First, five female nude mice (5-6 weeks old) were injected subcutaneously with a single dose of 5×10 6 MDA-MB-231-GFP human breast cancer cells. When the tumor size reached 1 cm 3 , the tumor tissue was harvested and cut into 1 mm 3 fragments. Then, 40 female nude mice (5-6 weeks old) were implanted orthotopically with a single tumor fragment in the fat pad of the second left mammary gland.
Digital gene expression (DGE) sequencing
RNA extraction and preparation can be found in Supplementary Materials and Methods.
Clustering and sequencing (Novogene, Beijing, China): The clustering of the index-coded samples was performed on a cBot Cluster Generation System using a TruSeq PE Cluster Kit v3-cBot-HS (Illumina, San Diego, CA, USA) according to the manufacturer's instructions. After cluster generation, the library preparations were sequenced on an Illumina Hiseq 2000/2500 platform, and 100 bp/50 bp single-end reads were generated.
Differential expression analysis (Novogene, Beijing, China): Differential expression analysis was performed using the DESeq R package (Version 1.10.1). DESeq provided statistical routines for determining differential expression in digital gene expression data using a model based on the negative binomial distribution. The resulting P-values were adjusted using the Benjamini and Hochberg's approach for controlling the false discovery rate. Genes with an adjusted P<0.05 found by DESeq were assigned as differentially expressed. Then we applied pathway enrichment analysis using Kyoto Encyclopedia of Genes and Genomes (KEGG) with the Database for Annotation, Visualization and Integrated Discovery (DAVID). A heat map was drawn with Heml software (Version 1.0, Heatmap Illustrator, Wuhan, China).
qRT-PCR analysis
For mRNA detection, cDNAs were synthesized from 2 μg total RNA extracted from cells and tissues using oligo-d (T) 15 primers and Moloney murine leukaemia virus (MMLV, Invitrogen, Thermo Fisher Scientific, MA, USA). qRT-PCR was performed by using SYBR Green PCR Master Mix (Toyobo, Osaka, Japan) on LightCycler ® 480 Real-Time PCR System (Roche Molecular Diagnostics, Pleasanton, CA, USA). The primer sequences were as follows: glyceraldehyde-3-phosphate dehydrogenase (GAPDH) sense: 5'-GACCCCTTCATTGACCTCAA C-3'; GAPDH anti-sense: 5'-CTTCTCCATGGTGG TGAAGA-3'; ARHGAP5 sense: 5'-CATCTGTTT TTGGCCAACCT-3'; ARHGAP5 anti-sense: 5'-GT GGAGGAGCCACAATGTTT-3'; ITGB1 sense: 5'-AA ATGGGCCTGTTCTTGATG-3'; and ITGB1 antisense: 5'-TTCTCCACAGTCCAGCAAGA-3'. The relative amount of genes was normalized to GAPDH. Data were calculated based on 2 -ΔCt where ΔCt = Ct TargetCt Reference . Fold change was calculated by the 2 -ΔΔCt method.
Western blotting
Protein was extracted from cells and tissues using RIPA buffer containing a complete protease and phosphatase inhibitor cocktail (Roche, Mannheim, Germany). Protein (20 μg) was separated by electrophoresis on 8% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels and blotted onto polyvinylidene fluoride (PVDF) membranes (Millipore, Darmstadt, Germany). Rabbit anti-ITGβ1 (1:2,000, Abcam, San Francisco, CA, USA); rabbit anti-ITGβ8 (1:1,000, Abcam); rabbit anti-ARHGAP5 (1:500, Abcam); rabbit anti-Phospho-Akt (Ser473) (1:1,000 dilution, Cell Signaling Technology, Danvers, MA, USA); on rabbit anti-Akt (1:1,000 dilution, Cell Signaling Technology), rabbit anti-GAPDH (1:1,000 dilution, Cell Signaling Technology) were used as primary antibodies. Horse radish peroxidase (HRP)-conjugated goat anti-rabbit (cwBiotech, Beijing, China) was used as the secondary antibody. Signals were visualized with chemiluminescence (Millipore, MA, USA).
IHC analysis
Frozen breast cancer tissues were embedded in optimal cutting temperature (OCT) compound (Sakura Finetek USA Inc., Torrance, CA, USA) and sliced using a cryostat. Slides were dried and fixed with 4% paraformaldehyde and stored in 4 °C. Slides were microwaved in 10 mM sodium citrate buffer before incubation with the primary antibodies against ARHGAP5 (1:300, Abcam) or ITGβ1 (1:400, Abcam) overnight at 4 °C. Slides were washed with PBS and incubated with streptavidin-horseradish peroxidaseconjugated goat secondary antibody (DAKO, Santa Clara, CA, USA) for 30 min at room temperature. The color was developed using diaminobenzidine. Finally, the slides were counter-stained with hematoxylin.
Statistical analysis
Each cell experiment was performed three times (n=3). The number of animals in each group was 10 (n=10). All experimental data were graphed and analyzed by GraphPad Prism 6 (GraphPad Software, Inc., San Diego, CA, USA). Comparisons between two groups were performed with two tailed unpaired t test. Welch correction was applied when necessary. Lung metastasis occurrence was analyzed with the χ 2 test. Data are presented as . P<0.05 were considered statistically significant.
More information on Material and Methods can be found in Supplementary Materials and Methods.
Results
ETBM inhibited TNBC cell proliferation in vitro
For better visualization on cell morphology, we adopted the IncuCyte® ZOOM live-cell assay. With pictures taken from IncuCyte ® on 24 h of ETBM treatment, we could observe vigorously growing cells with GFP expression in the control wells, whereas only dead cells with disabled GFP expression in 480 μg/mL ETBM treatment wells ( Figure 1A) . Intriguingly, when treated with 60 μg/mL ETBM, cells generated many vesicles with no GFP expression ( Figure 1A) . We further calculated the IC 50 on MDA-MB-231-GFP by IncuCyte ® -based phaseconfluence and fluorescence-confluence. And it was 63.56 μg/mL and 87.71 μg/mL, respectively ( Figure 1B) . Since the range is rather wide, we confirmed the IC 50 adopting the crystal violet techniques. The estimated IC 50 by crystal violet was 81.49 μg/mL on 24 h and 76.01 μg/mL on 48 h ( Figure 1C) . Furthermore, we investigated the IC 50 of two different TNBC cell lines, SUM-149 and MDA-MB-468 ( Figure 1D, E) , which was 55.00 μg/mL and 45.35 μg/mL on 24 h, respectively. These results suggest that ETBM inhibits the proliferation of TNBC cell in a dosedependent manner. 
ETBM undermined the migration and invasion abilities of TNBC cells
Migration and invasion of MDA-MB-231-GFP cells were inhibited by ETBM in 30 μg/mL and 60 μg/mL (Figure 2A,   B) . Migrating ETBM-treated cells became rounder with less focal adhesions than the control cells, where filopodia were often seen at the extremities. The wound-healing assay revealed that after 24 h, the wound in ETBM-treated cells healed much more slowly than that of untreated cells (P<0.01) ( Figure 2C ).
ETBM suppressed TNBC progression and lung metastasis in vivo
Tumors growth was inhibited in both high-dose (50 mg/kg) ETBM group (ETBM-H) and low-dose (30 mg/kg) ETBM group (ETBM-L) ( Figure 3A, B, E) . ETBM-H exhibited smaller tumor size compared to controls from d 10 (P<0.01). On sacrifice, tumors in ETBM-H displayed significantly lower weight compared to the untreated group (P<0.001). ETBM-L also showed meaningful inhibition on tumors (P<0.05). Moreover, ETBM-H notably suppressed lung metastasis occurrence (P<0.05) ( Figure 3C ).
Body weight and toxicity
During the course of the experiment, no physical or behavioral signs indicated adverse effects were observed in the animals in the ETBM treatment group. A stable bodyweight gain from d 0 to d 35 in all groups was observed ( Figure 3D ). 
Gene expression analysis of ETBM treated and untreated cells
Gene expression differences were detected in 665 genes, with 275 genes up-regulated and 390 genes down-regulated after ETBM treatment. KEGG analysis indicates that focal adhesion and extracellular matrix (ECM) might be significant pathways that were influenced by ETBM treatment ( Figure 4A) . We then identified genes involved in these two pathways from the differential expression analysis and illustrated them on the heat map ( Figure 4B) . Integrins are the major transmembrane receptors mediating cell adhesion to ECM proteins (27) and ARHGAP5 (p190 RhoGAP) has an essential role in integrin-dependent adhesion signaling and cytoskeleton organization (28) . Moreover, in TNBC, altered ECM can impair tumor's response to therapeutics and promote progression along with metastasis (29) . Therefore, we decided to investigate these proteins further to understand the biological mechanisms involved with ETBM treatment of TNBC.
Decreased expression of ARHGAP5 and integrins in ETBM-treated cell and tumors
qRT-PCR and Western blotting were performed to further confirm the expression of ARHGAP5, ITGβ1 and ITGβ8 in ETBM treated cells (Figure 5A-D) . There was reduction of mRNA and protein expression of ARHGAP5 and ITGβ8 in ETBM-treated cells, whereas ITGβ1 was decreased only at the protein level ( Figure 5C, D) . As for tumor samples, we observed suppressed expression of ARHGAP5, ITGβ1, and ITGβ8 in ETMB-treated groups ( Figure 5E ). Then IHC analysis verified reduction in ITGβ1 on the cell membrane and ARHGAP5 in the cytoplasm ( Figure 5F ). These data suggest that ETBM down-regulated these mobility-related proteins and this could contribute to the paralyzed migration and lesser metastases. 
Discussion
According to Pharmacopoeia of the People's Republic of China, the dosage of Tubeimu on human is 4.5 to 9.0 g. The main chemicals in Tubeimu are saponins, sterol compounds, alkaloids, maltol.I, e-modin.II, adenosine, etc. (30) . In former studies regarding Tubeimu, one revealed that the aqueous extract from Tubeimu and Fuzi (Radix Aconiti Lateralis Preparata) had synergetic inhibitory effects on the growth of MDA-MB-231 cells and they obtained the same results with tubeimoside I and acetylbenzoylaconine, two well identified active compounds in these herbs (31). Our study adopted dichloromethane as extracting agent and fresh Tubeimu as samples for obtaining liposoluble chemicals, since our previous research showed the main compounds in ETBM are sterols instead of saponins (32). Besides the anti-proliferation effect, we observed inhibition on metastasis, cell migration and change in cell morphology, which may be caused by unidentified active compounds in ETBM. Furthermore, ETBM showed the efficacy without apparent toxicity. Low toxicity is among the advantages of using nature-developed medicine. ETBM has the potential to be developed into therapeutics for TNBC treatment. Developing an effective drug is a longterm endeavor and the exact active chemicals in ETBM need extensive study by multidisciplinary groups. We illustrate that ETBM hindered the expression of ITGβ1, ITGβ8, and ARTHGAP5 in treated cells and tumors, which indicates that the decreasing cell motility and tumor metastasis may be a result of down-regulation of the integrin/ARHGAP5 pathway. ARHGAP5 protein was concentrated along filopodial shafts in cells, but was absent at the leading edge in lamellipodial protrusions (33) . This could explain the morphological change we observed in the migrated cells. According to our study, the integrin/ ARHGAP5 could be a potential target of ETBM. However, how the chemicals in ETBM interact with tumor ECM and influence the specific localization and quantity of integrins/ARHGAP5 needs further research.
By IncuCyte ® photography, we observed plenty of intracellular vesicles in 60 μg/mL ETBM treated cells. Without access to electron microscope (EM), it was difficult to have a clear picture on what these vesicles contained. Nonetheless, in this case, they were unlikely to be transporting or secretory vesicles. We highly speculate that these vesicles were autophagosomes in the process of autophagy. The role of autophagy in cancer is controversial (34, 35) . It is necessary for cancer cells to adapt efficiently to hypo-nutrient environment, since protein degradation process leads to amino acid recycling and provides sufficient nutrients for cell survival (35) . However, uncontrolled autophagy can induce autophagic cell death (ACD) (35) . ACD is featured by the large-scale engulfment of portions of the cytoplasm in autophagosomes, giving the cell a special vacuolated appearance (36) , like what we observed here. Autophagy can be destructive to cells by damaging the mitochondria, or degradation of vital proteins (37) . The cells treated by ETBM lost viability and accumulated large vacuoles, which indicates autophagy may be among the mechanisms in the cause of their death. Autophagy related pathways, like phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR, are to be studied in future studies.
